TABLE 1.

Demographics and Baseline Data of 9 HIV-Infected Men With Acute Hepatitis C Infection

		HCV Exposure		At Time of HCV Diagnosis
						Plasma HIV
Patient	Age	MSM	Parenteral*	ARV	CD4 (cells/mm3)	RNA (copies/mL)	HCV Antibody
1	47	Y	No	3TC, D4T, NFV	292	<50	Positive
2	26	Y	No	None	355	39,556	Negative
3	56	Y	No	3TC, TDF, EFV	350	<50	Positive
4	35	Y	No	3TC, D4T, NVP	435	5000	Positive
5	50	N	Prior IDU	3TC, ZDV, NFV	329	<50	Positive
6	55	Y	No	3TC, ABC, FOS/r	450	<50	Positive
7	38	Y	No	3TC, TDF, ATZ	283	<50	Positive
8	45	N	No	DDI, TDF, IDV/r	7	>100,000	Negative
9	33	N	Active IDU	DDI, NVP, LOP/r	312	30,000	Negative

Patient	Age	Clinical Presentation	Sexually Transmitted Infections	ALT Peak Value (IU/L)	HCV Therapy	Outcome
1	47	Jaundice, RUQ pain	—	1473	Declined therapy	Spontaneous clearance of HCV viremia
2	26	Diarrhea, Arthralgia	—	361	Declined therapy	Spontaneous clearance of HCV viremia
3	56	Jaundice, Nausea	—	>3000	PEG IFN + RBV	SVR
4	35	Jaundice, RUQ pain	Urethral GC 4 weeks prior to HCV diagnosis	426	PEG IFN + RBV	ETR
5	50	Flu-like illness, Headache	Urethral Chlamydia 7 months prior to HCV diagnosis	286†	PEG IFN + RBV	SVR
6	55	Jaundice, Flu-like illness, RUQ pain	—	2128	PEG IFN + RBV	Chronic HCV
7	38	Asymptomatic	Rectal GC 1 month prior to HCV diagnosis	1194	Declined therapy	Chronic HCV
8	45	Asymptomatic	—	334	Declined therapy	Chronic HCV
9	33	Jaundice, Diarrhea, Myalgia	—	4722	Therapy not offered	Chronic HCV

^*Surgery within one year, history of blood tranfusion, reported IDU.

^†Peak ALT from hospitalization not available.

3TC indicates lamivudine; ABC, abacavir; ATZ, atazanavir; D4T, stavudine; DDI, didanosine; EFV, efavirenz; ETR, end of treatment response; FOS/r, ritonivir-boosted fosamprenavir; GC, gonorrhea; IDV/r, ritonavir-boosted indinivir; LOP/r, ritonivir-boosted lopinivir; PEG IFN, pegylated infeferon; NVP, nevirapine; NFV, nelfinivir; RBV, ribavirin; SVR, sustained virologic response; TDF, tenofovir; ZDV, zidovudine; and MSM, men who have sex with men.